Capital Advisors Ltd. LLC Has $344,000 Holdings in Pfizer Inc. (NYSE:PFE)

Capital Advisors Ltd. LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 4.3% during the first quarter, Holdings Channel.com reports. The firm owned 13,566 shares of the biopharmaceutical company’s stock after selling 616 shares during the period. Capital Advisors Ltd. LLC’s holdings in Pfizer were worth $344,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of PFE. Tallon Kerry Patrick acquired a new position in shares of Pfizer during the fourth quarter worth approximately $509,000. Brighton Jones LLC raised its position in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its position in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the period. Stonebridge Financial Group LLC acquired a new position in shares of Pfizer during the fourth quarter worth approximately $193,000. Finally, Sovran Advisors LLC acquired a new position in shares of Pfizer during the fourth quarter worth approximately $922,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Trading Up 0.6%

NYSE PFE opened at $24.46 on Thursday. The stock has a market capitalization of $139.04 billion, a price-to-earnings ratio of 17.34, a PEG ratio of 0.64 and a beta of 0.57. The business’s fifty day moving average is $22.96 and its 200-day moving average is $24.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.82 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.03%. Pfizer’s payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.